Analysis of the latest price and medical insurance reimbursement status of Belzutifan in 2025

Belzutifan (Belzutifan) is an oral small molecule HIF-2α inhibitor. It mainly inhibits the activity of hypoxia-inducible factor 2α (HIF-2α), blocking tumor growth and angiogenesis signaling pathways in hypoxic environments. The drug is mainly used clinically to treat clear cell renal cell carcinoma and other HIF-2α-dependent tumors associated with VHL (Von Hippel-Lindau) syndrome. By targeting the hypoxia signaling pathway, Belzutifan can effectively inhibit tumor progression and provide new treatment options for some advanced or unresectable patients.

As of2025, besotivan has been officially approved for marketing in China, but has not yet been included in the national medical insurance system. This means that patients need to bear all the cost of medicines purchased in domestic hospitals, and the prices are relatively high. Since it is not covered by medical insurance, patients need to evaluate their financial affordability in advance when using this drug, and communicate with their doctors about the treatment cycle and medication plan to ensure continuity of treatment.

The price of domestic original drugs is relatively high, and you need to consult local hospital pharmacies for specific costs, but usually the price of each bottle may be tens of thousands of yuan. In contrast, the price of generic drugs abroad, especially the Laotian version, is relatively affordable, only about more than 5,000 yuan, and its active ingredients are basically the same as the original drugs, which can reduce the economic burden on patients. This difference provides patients with more choices, but when purchasing overseas drugs, it is necessary to ensure that the channels are formal and legal to ensure drug quality and safety.

Clinically, besotivan is suitable for patients with clear cell renal cell carcinoma associated with VHL syndrome, some advanced solid tumors, and HIF-2α-dependent tumors. Patients need to regularly monitor changes in blood routine, liver and kidney function and blood pressure during medication to prevent possible adverse reactions such as anemia or hypertension. Since the drug is expensive and not covered by medical insurance, patients should fully communicate with their doctor before treatment, including treatment schedule, cost budget and potential alternatives, to ensure that the treatment is safe, continuous and economically feasible.

Reference materials:https://www.drugs.com/